Acelyrin raises $250m through Series B round
Acelyrin has raised $250m through the series B financing round to license and acquire other programmes with focus on immunology. The funding round was led by Matrix Capital
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation by the European regulatory authorities for Novo Nordisk’s anti-obesity medication Wegovy.